Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.60 |
| ▸ | MAOB | P27338 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 6/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | CFD | P00746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442125 | 1.00 | MAOA (0.60) | MAOAMAOBKDM4EKIF11F2 | |
| SCHEMBL24242349 | 0.87 | F2 (0.49) | MAOAMAOBKDM4EKIF11F2 | |
| SCHEMBL29442143 | 0.87 | MAPT (0.54) | MAOAMAOBKIF11F2CFD | |
| SCHEMBL10619033 | 0.87 | MAPT (0.54) | MAOAMAOBKIF11F2CFD | |
| SCHEMBL10342860 | 0.83 | KIF11 (0.51) | MAOAMAOBKIF11F2CFD | |
| SCHEMBL24242375 | 0.81 | F2 (0.49) | MAOAMAOBKIF11F2CFD | |
| SCHEMBL17260679 | 0.79 | NOS1 (0.56) | MAOAMAOBKDM4EKIF11 | |
| SCHEMBL29891935 | 0.77 | MAOA (0.61) | MAOAMAOBKDM4EF2CFD | |
| SCHEMBL694149 | 0.77 | MAOA (0.61) | MAOAMAOBKDM4EF2CFD | |
| SCHEMBL12847264 | 0.76 | KDM4E (0.57) | MAOAMAOBKDM4EKIF11F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| EP-3947667-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| CN-113993997-A | Modified cleaving enzymes, uses thereof and related kits | ENCODIA 公司 | 2022-01-28 | — | — | CN | claimed |
| WO-2020198264-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2020-10-01 | — | — | WO | claimed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-26 | — | — | US | disclosed |
| US-11788080-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-112062730-B | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2023-09-29 | — | — | CN | disclosed |
| US-20230257727-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | disclosed |
| US-4346032-A | ANTIDOTES TO OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346034-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346035-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346036-A | ALKYLATION; AMIDATION; TRANQUILIZER ANTAGONIST | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4316839-A | Imidazodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | disclosed |
| EP-0027214-A1 | Imidazodiazepine derivatives, process and intermediates for their preparation, medicaments containing them and their therapeutic application | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-22 | — | — | EP | disclosed |
| US-3984562-A | TREATING ANXIETY | AMERICAN CYANAMID COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | MAOA 120/4885MAOB 253/4885KDM4E 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.